Search Orphan Drug Designations and Approvals
-
Generic Name: | imatinib | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Gleevec | ||||||||||||||||
Date Designated: | 10/11/2005 | ||||||||||||||||
Orphan Designation: | Treatment of Philadelphia-positive acute lymphoblastic leukemia | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Novartis Pharmaceuticals Corporation One Health Plaza Mail Code 105/1E870D East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | imatinib |
---|---|---|
Trade Name: | Gleevec | |
Marketing Approval Date: | 10/19/2006 | |
Approved Labeled Indication: | Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) | |
Exclusivity End Date: | 10/19/2013 | |
Exclusivity Protected Indication* : | ||
2 | Generic Name: | imatinib |
---|---|---|
Trade Name: | Gleevec | |
Marketing Approval Date: | 01/25/2013 | |
Approved Labeled Indication: | Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy | |
Exclusivity End Date: | 01/25/2020 | |
Exclusivity Protected Indication* : | Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy | |
-